Skip to content
2000
Volume 5, Issue 4
  • ISSN: 1573-3998
  • E-ISSN: 1875-6417

Abstract

All forms of diabetes are increasing in prevalence, but with the advent of the obesity epidemic, we now face the prospect of an increasing number of women conceiving whilst taking traditional oral antidiabetic agents (OADs). This is also further complicated by the availability of new incretin-based therapies, the dipeptidylpeptidase-4 (DPP-IV) inhibitors and glucagon-like-1 receptor (GLP-1R) analogues. Original concerns regarding the use of such OADs have meant that diet control and insulin has been the mainstay of treatment for hyperglycaemia during pregnancy. However, recent NICE guidelines have suggested a role for oral antidiabetic agents. Safety is of paramount concern, especially in pregnancy, and this review will discuss the evidence to date.

Loading

Article metrics loading...

/content/journals/cdr/10.2174/157339909789804350
2009-11-01
2025-05-19
Loading full text...

Full text loading...

/content/journals/cdr/10.2174/157339909789804350
Loading

  • Article Type:
    Research Article
Keyword(s): DPP-IV inhibitors; GLP-1 analogues; Metformin; OADs; Pregnancy; Sulphonylureas; TZDS
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test